Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global Phase 2 Study to Evaluate the Efficacy and Safety of ARX788 for Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors

NCT05041972 is registered in ClinicalTrials.gov with Ambrx, Inc. as lead sponsor.

NCT NCT05041972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05041972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global Phase 2 Study to Evaluate the Efficacy and Safety of ARX788 for Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors
Lead sponsor
Ambrx, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
November 5, 2021
Completion date
April 20, 2022
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

her2 amplified solid tumors, her2 mutation-related tumors